AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 241 min read$TXG

Saxonov Serge sold $2.0M of TXG

Saxonov Serge (Chief Executive Officer) sold 25,000 shares of 10x Genomics, Inc. (TXG) at an average of $81.22 ($78.23–$82.36, $2.03M total) across 5 trades on 2026-09-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Saxonov Serge
Published Sep 24, 2026, 8:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TXG
Bearish
medium confidence
Mentioned
$TXG
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TXGBearishLow
01

Why it matters

Provides fresh, primary‑source data on insider activity, useful for short‑term traders.

02

Market read

Insider sale of $2M may cause slight negative pressure; relevance modest.

03

What to watch

Potential upcoming earnings or product news may outweigh the sale.

Relevance 5/10Novelty 7/10Timing: filed 2026-09-24 (post‑market)

Background

Form 4 filing discloses a 10b5‑1 planned sale by 10x Genomics' CEO.

Company-level read

Ticker impact

$TXGBearishMedium confidence
Context

CEO Serge Saxonov sold 25,000 shares for $2.03M via a 10b5‑1 plan on 2026‑09‑22.

Expected impact

Modest downside risk, likely 1‑2% dip.

Evidence & confidence

A $2M sale by the chief executive is material but not large enough to trigger a sharp move.

Market effects

Sector

Minimal impact on the genomics sector; insider sales are common.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • Person
    Saxonov Serge

    Chief Executive Officer of 10x Genomics

  • Company
    10x Genomics, Inc.

    US‑listed genomics technology firm (ticker TXG)

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TXG insider trading history →

Related articles

SEP 24
$TXGMed

TXG Stock Jumps As AI Partnership And Legal Win Shift Outlook

10x Genomics Inc. (TXG) stock rose 13.01% on September 24, 2026, driven by an AI partnership with Lunit and a patent win against Qiagen. The company's stock has surged from $59.98 to $84.11 over recent weeks. TXG reported $642.8M in revenue with strong gross margins but negative operating margins. Analysts have mixed views, with price targets ranging from $60s to $70.

timothysykes.com3 min
SEP 24
$TXGMed

TXG Stock Jumps As AI Deal And Legal Win Shift Momentum

10x Genomics Inc. (TXG) stock rose 12.23% on September 24, 2026, driven by investor optimism over AI partnerships and a legal win. The company's stock has increased over 35% in under a month, reaching $84.91. TXG reported $151M in quarterly revenue with a 70% gross margin but remains unprofitable. Analysts have mixed views, with targets around $70, while traders focus on momentum and future growth potential.

timothysykes.com3 min
SEP 3
$TXGMed

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?

10x Genomics (TXG) has risen 84% in 3 months, driven by consumables growth and Atera demand. Q2 2026 consumables revenue increased 7% YoY, with Single Cell up 3% and Spatial up 16%. Management raised 2026 revenue guidance to $610M-$630M. However, instrument sales fell 47.2% YoY, and the company reported a $19.6M operating loss. TXG trades at 11.9X forward sales, a premium to peers.

tradingview.com3 min
AUG 18
$TXGMed

10x Genomics (TXG) Sees Strong Early Orders for New Atera Platform

10x Genomics (NASDAQ:TXG) reported Q2 revenue of $151m, including a $1.6m Takara settlement; excluding it, revenue was $149.4m, up 3% YoY. Atera booked orders already exceed planned 2026 shipments (~40 units). Cash rose to $552m and gross margin to 74%. Full-year revenue guidance raised to $610m-$630m; instrument revenue fell 47% YoY.

yahoo.com3 min
AUG 14
$TXGMedAI 9/10

10x Genomics (TXG) Q2 2026 Earnings Call Transcript

10x Genomics (TXG) reported Q2 2026 revenue of $151.0 million, up 3% YoY excluding non-recurring patent settlement revenue. Gross margin was 74%. FY2026 revenue guidance is $610 million to $630 million. Booked Atera orders exceed the 2026 shipment target of 40 units, with capacity as the constraint. Net loss was $17.9 million.

fool.com10 min